Adjuvant Therapies for Renal Cell Carcinoma - Robert Uzzo

(Length of discussion - 21 minutes)

David Crawford discusses adjuvant therapy in kidney cancer with Rober Uzzo, and the fact that although there have been three decades of trials, there is still no approved therapies to treat the disease. However, Dr. Uzzo points to the S-TRAC trial as a step forward in that research space.


Related Content:
Watch: Over-treatment of Renal Tumors: The Turtle in the Room - Robert G. Uzzo

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)

A phase III study of atezolizumab vs placebo as adjuvant therapy in renal cell carcinoma patients at high risk of recurrence following resection (IMmotion010)

Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies 

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Biographies: 

Robert G. Uzzo, MD 

Chair, Department of Surgical Oncology
G. Willing "Wing" Pepper Chair in Cancer Research
Kidney, Bladder, and Prostate Cancer TRDG Member
Senior Vice-President, Physician Services
President, FCCC Medical Group, Inc.
Professor of Surgery, Temple University Health System